Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2

Oncotarget

Volumn 6, Issue 39, 2015, Pages 41692-41705

  Tung, Min Che ^a,b   Lin, Po Lin ^c   Wang, Yao Chen ^d   He, Tsung Ying ^c   Lee, Ming Ching ^e   Yeh, Sauh Der ^a   Chen, Chih Yi ^c   Lee, Huei ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin sensitivity; Lung cancer; Nrf2; P53

Indexed keywords

CISPLATIN; HEME OXYGENASE 1; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PROTEIN BCL X; SP1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

AGED; ARTICLE; BCL 2 GENE; BCL XL GENE; BINDING AFFINITY; BINDING SITE; CANCER RESISTANCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; NRF2 GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR CELL LINE; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NF-E2-RELATED FACTOR 2; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSFECTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84951854535     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6150     Document Type: Article

References (39)

1. Jin J, Sklar GE, Min Sen Oh V and Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Therapeutics and clinical risk management. 2008; 4:269-286.
2. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings. 2008; 83:584-594.
3. Tiseo M, Ardizzoni A and Boni L. First-Line Chemotherapy Treatment of Advanced Non-Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference? Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2014; 9:e82.
4. Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ and Whittle J. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. an analysis of Veterans Health Administration data. Journal of thoracic oncology. 2014; 9:702-709.
5. Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, Tsukamasa Y, Ito M and Nozawa Y. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free radical research. 2011; 45:1033-1039.
6. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS and Doetsch PW. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PloS one. 2013; 8:e81162.
7. Villeneuve NF, Sun Z, Chen W and Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell cycle. 2009; 8:3255-3256.
8. Nguyen T, Nioi P and Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. The Journal of biological chemistry. 2009; 284:13291-13295.
9. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nature reviews Drug discovery. 2013; 12:931-947.
10. Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox biology. 2013; 1:45-49.
11. Zucker SN, Fink EE, Bagati A, Mannava S, Bianchi-Smiraglia A, Bogner PN, Wawrzyniak JA, Foley C, Leonova KI, Grimm MJ, Moparthy K, Ionov Y, Wang J, Liu S, Sexton S, Kandel ES, et al. Nrf2 amplifies oxidative stress via induction of Klf9. Molecular cell. 2014; 53:916-928.
12. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS medicine. 2006; 3:e420.
13. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular cell. 2006; 21:689-700.
14. Yoo NJ, Kim HR, Kim YR, An CH and Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology. 2012; 60:943-952.
15. Miura S, Shibazaki M, Kasai S, Yasuhira S, Watanabe A, Inoue T, Kageshita Y, Tsunoda K, Takahashi K, Akasaka T, Masuda T and Maesawa C. A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance. The Journal of investigative dermatology. 2014; 134:553-556.
16. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ and Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. The Journal of pathology. 2010; 220:446-451.
17. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T and Yamamoto M. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia. 2011; 13:864-873.
18. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK and Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008; 29:1235-1243.
19. Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A and Morel F. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. European journal of cancer. 2009; 45:2219-2227.
20. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K and Yamamoto M. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:3423-3432.
21. Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N and Jiang T. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PloS one. 2013; 8:e63404.
22. Niture SK and Jaiswal AK. Nrf2-induced antiapoptotic BclxL protein enhances cell survival and drug resistance. Free radical biology & medicine. 2013; 57:119-131.
23. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM and MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood. 2012; 120:5188-5198.
24. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK and Zhang DD. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer research. 2014; 74:7430-41.
25. Rotblat B, Melino G and Knight RA. NRF2 and p53: Januses in cancer? Oncotarget. 2012; 3:1272-1283.
26. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D and Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Molecular cell. 2009; 34:663-673.
27. Asher G, Lotem J, Kama R, Sachs L and Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:3099-3104.
28. You A, Nam CW, Wakabayashi N, Yamamoto M, Kensler TW and Kwak MK. Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of p53 signaling by Nrf2. Archives of biochemistry and biophysics. 2011; 507:356-364.
29. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T and Cimino F. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. The Journal of biological chemistry. 2006; 281:39776-39784.
30. Niture SK and Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. The Journal of biological chemistry. 2012; 287:9873-9886.
31. Srisook K, Kim C and Cha YN. Molecular mechanisms involved in enhancing HO-1 expression: de-repression by heme and activation by Nrf2, the "one-two" punch. Antioxidants & redox signaling. 2005; 7:1674-1687.
32. Tan Q, Wang H, Hu Y, Hu M, Li X, Aodeng Q, Ma Y, Wei C and Song L. Src/STAT3-dependent HO-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer science. 2015; 106:1023-32.
33. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, Buchler MW and Friess H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11:3790-3798.
34. Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, Chen CY and Lee H. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Annals of surgical oncology. 2008; 15:3272-3277.
35. Chiou YH, Wong RH, Chao MR, Chen CY, Liou SH and Lee H. Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer patients. Environmental and molecular mutagenesis. 2014; 55:624-632.
36. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG and Oren M. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammationassociated colorectal cancer. Cancer cell. 2013; 23:634-646.
37. Ko JL, Cheng YW, Chang SL, Su JM, Chen CY and Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. International journal of cancer Journal international du cancer. 2000; 89:265-270.
38. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475:106-109.
39. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW and Lee H. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:1895-1905.